Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

NCT04918147 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT04918147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04918147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 2
Overall status
Terminated
Start date
October 13, 2021
Completion date
January 4, 2024
Enrollment
8 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

igg4 related disease, igg4-rd